Medications with anticholinergic activity increase the cumulative risk of cognitive impairment and death, according to findings from a study published online June 24 in the Journal of the American Geriatric Society.
Medications with anticholinergic activity increase the cumulative risk of cognitive impairment and death, according to findings from a study published online June 24 in the Journal of the American Geriatric Society.
The authors examined data from an ongoing observational study (Medical Research Council Cognitive Function and Ageing Study; MRC CFAS) to determine whether the use of these medications increased the risk of cognitive impairment and death in older people and whether there was a cumulative effect.
“Identifying risk factors for cognitive decline may lead researchers to a better understanding of clinical interventions to reduce the risk of developing Alzheimer’s disease,” the authors wrote. The use of anticholinergic medications has been associated with acute cognitive impairment in previous studies, the authors added. And these medications are used to treat a wide variety of conditions, many of which affect elderly patients, such as hypertension and congestive heart disease. However few studies have evaluated long-term exposure as a modifiable risk factor for cognitive decline, the authors said.
The study included 13,004 men and women aged 65 and older. Researchers found that 47% of participants reported taking medications with anticholinergic properties. The use of medication with definite anticholinergic effects was associated with a 0.33-point greater decline in Mini-Mental State Examination (MMSE) score (95% CI, 0.03–0.64; P=.03) than not taking anticholinergics. The use of possible anticholinergics at baseline was not associated with further decline (0.02, 95% CI, –0.14–0.11; P =.79). In addition, 2-year mortality was greater for those taking definite and possible anticholinergics. The researchers noted that as far as they knew, they may be the first to identify a link between mortality and anticholinergic burden, but due to the number and kinds of diseases these medications are used to treat, this finding should be viewed cautiously.
Clinicians should review cumulative anticholinergic burden in people presenting with cognitive impairment, the researchers noted.
“With a growing prevalence of cognitive impairment in the older adult population, prescribers should be aware of the potential effect that anticholinergics have on the development of cognitive and executive dysfunction and mortality,” the authors concluded.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.